{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T21:01:37Z","timestamp":1792530097604,"version":"4.5.0"},"reference-count":126,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Intern Med"],"published-print":{"date-parts":[[2026,5,1]]},"abstract":"<jats:sec id=\"ab-irv250005-1\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Cannabis use is common among those with mental health conditions, and many people report using cannabis to manage mental health symptoms. It is important for clinicians to understand the lack of clear benefits of cannabis for mental health conditions and the potential for substantial adverse effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-irv250005-2\">\n                    <jats:title>Observations<\/jats:title>\n                    <jats:p>Overall, the potential benefits of cannabis for mental health conditions remain poorly studied. There is low-certainty evidence that \u0394-9-tetrahydrocannabinol (THC)\u2013predominant cannabis may not improve symptoms of posttraumatic stress disorder, and there is largely insufficient evidence to characterize the effects of long-term THC-predominant cannabis use on anxiety, depression, and attention-deficit\/hyperactivity disorder. There is emerging low-certainty evidence that the cannabis constituent cannabidiol alone may reduce anxiety in patients with anxiety disorders. THC-predominant cannabis use holds substantial risk for adverse mental health effects, and counseling patients about these risks is crucial to promote safety. These risks include worsening mania symptoms and function in those with bipolar disorder and an increase in psychotic symptoms in those with psychotic spectrum disorders. Among people with past-year cannabis use, about 3 in 10 have cannabis use disorder (CUD), and about one-half those with CUD have moderate or severe disease with negative social, employment, or other adverse outcomes. Regular use of high THC-content products by adolescents and young adults is associated with several concerning risks, including an increased risk of psychosis (estimates range from about 2-fold to 11-fold increased risk), a higher risk of CUD, and self-harm in those with mood disorders. Cannabis use should be avoided in individuals at elevated risk of harms, including adolescents and young adults, those with bipolar or psychotic disorders, pregnant individuals, and those at risk for substance use disorders.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-irv250005-3\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>The current evidence base is not sufficient to support the use of cannabis for the treatment of mental health conditions and demonstrates substantial risks of adverse effects. Clinicians should engage patients with mental health conditions in discussions about cannabis use because use is common, has an influence on mental health symptoms, and is likely an important modifiable risk factor for mental health conditions in some populations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamainternmed.2025.8215","type":"journal-article","created":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T15:00:32Z","timestamp":1773068432000},"page":"618","source":"Crossref","is-referenced-by-count":22,"title":["Cannabis and Mental Health"],"prefix":"10.1001","volume":"186","author":[{"given":"Devan","family":"Kansagara","sequence":"first","affiliation":[{"name":"Center to Improve Veteran Involvement in Care (CIVIC), VA Portland Health Care System, Portland, Oregon"},{"name":"Department of Medicine, Oregon Health and Science University, Portland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garth E.","family":"Terry","sequence":"additional","affiliation":[{"name":"Mental Illness Research, Education, and Clinical Center, VA Puget Sound Health Care System, Seattle, Washington"},{"name":"Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chelsea K.","family":"Ayers","sequence":"additional","affiliation":[{"name":"Center to Improve Veteran Involvement in Care (CIVIC), VA Portland Health Care System, Portland, Oregon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak C.","family":"D\u2019Souza","sequence":"additional","affiliation":[{"name":"Neuropsychiatry Firm, Mental Health Service Line, VA Connecticut Healthcare System, West Haven"},{"name":"Department of Psychiatry, Yale School of Medicine, New Haven, Connecticut"},{"name":"Yale Center for the Science of Cannabis and Cannabinoids, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"9","key":"irv250005r1","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1111\/add.16519","article-title":"Changes in self-reported cannabis use in the United States from 1979 to 2022.","volume":"119","author":"Caulkins","year":"2024","journal-title":"Addiction"},{"issue":"6","key":"irv250005r2","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.bpsc.2020.12.016","article-title":"A comprehensive review of cannabis potency in the United States in the last decade.","volume":"6","author":"ElSohly","year":"2021","journal-title":"Biol Psychiatry Cogn Neurosci Neuroimaging"},{"issue":"5","key":"irv250005r3","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1111\/add.15253","article-title":"Changes in delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) concentrations in cannabis over time: systematic review and meta-analysis.","volume":"116","author":"Freeman","year":"2021","journal-title":"Addiction"},{"issue":"1","key":"irv250005r5","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3109\/00952990.2013.821477","article-title":"Self-reported cannabis use characteristics, patterns and helpfulness among medical cannabis users.","volume":"40","author":"Bonn-Miller","year":"2014","journal-title":"Am J Drug Alcohol Abuse"},{"issue":"7","key":"irv250005r6","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1111\/add.15342","article-title":"Heterogeneities in administration methods among cannabis users by use purpose and state legalization status: findings from a nationally representative survey in the United States, 2020.","volume":"116","author":"Shi","year":"2021","journal-title":"Addiction"},{"issue":"4","key":"irv250005r7","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1007\/s10900-021-01049-1","article-title":"Self-reported medical and nonmedical cannabis use: results from the 2018 Behavioral Risk Factor Surveillance System in 14 states.","volume":"47","author":"Schauer","year":"2022","journal-title":"J Community Health"},{"issue":"6","key":"irv250005r8","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.14809","article-title":"Cannabis use reported by patients receiving primary care in a large health system.","volume":"7","author":"Gelberg","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"3","key":"irv250005r9","doi-asserted-by":"publisher","DOI":"10.1016\/j.amepre.2025.107994","article-title":"Medical cannabis use across ages 19-65 years: U.S. young and middle adults, 2018-2023.","volume":"70","author":"Terry-McElrath","year":"2025","journal-title":"Am J Prev Med"},{"key":"irv250005r10","doi-asserted-by":"publisher","DOI":"10.1016\/j.addbeh.2021.106991","article-title":"Cannabis and mental health: prevalence of use and modes of cannabis administration by mental health status.","volume":"121","author":"Rup","year":"2021","journal-title":"Addict Behav"},{"issue":"10","key":"irv250005r11","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.7326\/ANNALS-24-03819","article-title":"High-concentration delta-9-tetrahydrocannabinol cannabis products and mental health outcomes: a systematic review.","volume":"178","author":"Rittiphairoj","year":"2025","journal-title":"Ann Intern Med"},{"issue":"10","key":"irv250005r12","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1016\/S2215-0366(16)30208-5","article-title":"Marijuana use and use disorders in adults in the USA, 2002-14: analysis of annual cross-sectional surveys.","volume":"3","author":"Compton","year":"2016","journal-title":"Lancet Psychiatry"},{"issue":"5","key":"irv250005r13","doi-asserted-by":"publisher","first-page":"282","DOI":"10.7326\/M18-0810","article-title":"Risks and benefits of marijuana use: a national survey of U.S. adults.","volume":"169","author":"Keyhani","year":"2018","journal-title":"Ann Intern Med"},{"issue":"22","key":"irv250005r14","doi-asserted-by":"publisher","first-page":"4488","DOI":"10.1002\/cncr.30879","article-title":"Cannabis use among patients at a comprehensive cancer center in a state with legalized medicinal and recreational use.","volume":"123","author":"Pergam","year":"2017","journal-title":"Cancer"},{"issue":"1","key":"irv250005r15","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1186\/s12875-021-01559-w","article-title":"Physicians\u2019 experiences, attitudes, and beliefs towards medical cannabis: a systematic literature review.","volume":"22","author":"R\u00f8nne","year":"2021","journal-title":"BMC Fam Pract"},{"issue":"9","key":"irv250005r18","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/S2215-0366(22)00161-4","article-title":"Association of cannabis potency with mental ill health and addiction: a systematic review.","volume":"9","author":"Petrilli","year":"2022","journal-title":"Lancet Psychiatry"},{"issue":"5","key":"irv250005r19","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1093\/schbul\/sbw003","article-title":"Meta-analysis of the association between the level of cannabis use and risk of psychosis.","volume":"42","author":"Marconi","year":"2016","journal-title":"Schizophr Bull"},{"issue":"3","key":"irv250005r20","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1093\/schbul\/sbz102","article-title":"Transition of substance-induced, brief, and atypical psychoses to schizophrenia: a systematic review and meta-analysis.","volume":"46","author":"Murrie","year":"2020","journal-title":"Schizophr Bull"},{"issue":"3","key":"irv250005r21","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/S2215-0366(15)00363-6","article-title":"Continued versus discontinued cannabis use in patients with psychosis: a systematic review and meta-analysis.","volume":"3","author":"Schoeler","year":"2016","journal-title":"Lancet Psychiatry"},{"key":"irv250005r22","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.jpsychires.2022.11.029","article-title":"Cannabis use in attention - deficit\/hyperactivity disorder (ADHD): a scoping review.","volume":"157","author":"Francisco","year":"2023","journal-title":"J Psychiatr Res"},{"issue":"7","key":"irv250005r26","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.biopsych.2015.12.002","article-title":"Acute and chronic effects of cannabinoids on human cognition-a systematic review.","volume":"79","author":"Broyd","year":"2016","journal-title":"Biol Psychiatry"},{"issue":"7","key":"irv250005r27","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1111\/add.15764","article-title":"Evidence on the acute and residual neurocognitive effects of cannabis use in adolescents and adults: a systematic meta-review of meta-analyses.","volume":"117","author":"Dellazizzo","year":"2022","journal-title":"Addiction"},{"issue":"2","key":"irv250005r28","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1017\/S0033291720005036","article-title":"Intelligence quotient decline following frequent or dependent cannabis use in youth: a systematic review and meta-analysis of longitudinal studies.","volume":"51","author":"Power","year":"2021","journal-title":"Psychol Med"},{"key":"irv250005r31","doi-asserted-by":"publisher","first-page":"j4008","DOI":"10.1136\/bmj.j4008","article-title":"AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both.","volume":"358","author":"Shea","year":"2017","journal-title":"BMJ"},{"key":"irv250005r32","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/j.neubiorev.2019.09.036","article-title":"How does cannabidiol (CBD) influence the acute effects of delta-9-tetrahydrocannabinol (THC) in humans? a systematic review.","volume":"107","author":"Freeman","year":"2019","journal-title":"Neurosci Biobehav Rev"},{"issue":"3","key":"irv250005r33","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.neuron.2022.12.022","article-title":"THC and CBD: similarities and differences between siblings.","volume":"111","author":"Stella","year":"2023","journal-title":"Neuron"},{"issue":"4","key":"irv250005r34","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1111\/add.16700","article-title":"Quantity of delta-9-tetrahydrocannabinol consumption and cannabis use disorder among daily cannabis consumers.","volume":"120","author":"Borodovsky","year":"2025","journal-title":"Addiction"},{"key":"irv250005r35","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.drugalcdep.2014.08.005","article-title":"Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications.","volume":"144","author":"Castaneto","year":"2014","journal-title":"Drug Alcohol Depend"},{"key":"irv250005r36","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1146\/annurev-psych-113011-143739","article-title":"The endocannabinoid system and the brain.","volume":"64","author":"Mechoulam","year":"2013","journal-title":"Annu Rev Psychol"},{"issue":"6","key":"irv250005r37","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.bpsc.2020.07.016","article-title":"Review of the endocannabinoid system.","volume":"6","author":"Lu","year":"2021","journal-title":"Biol Psychiatry Cogn Neurosci Neuroimaging"},{"key":"irv250005r38","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.drugalcdep.2013.12.008","article-title":"Using cannabis to help you sleep: heightened frequency of medical cannabis use among those with PTSD.","volume":"136","author":"Bonn-Miller","year":"2014","journal-title":"Drug Alcohol Depend"},{"issue":"4","key":"irv250005r39","doi-asserted-by":"publisher","first-page":"458","DOI":"10.7326\/M23-2811","article-title":"Trends in U.S. medical cannabis registrations, authorizing clinicians, and reasons for use from 2020 to 2022.","volume":"177","author":"Boehnke","year":"2024","journal-title":"Ann Intern Med"},{"key":"irv250005r40","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.addbeh.2017.01.008","article-title":"Medicinal versus recreational cannabis use: patterns of cannabis use, alcohol use, and cued-arousal among veterans who screen positive for PTSD.","volume":"68","author":"Loflin","year":"2017","journal-title":"Addict Behav"},{"issue":"3","key":"irv250005r41","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0246990","article-title":"The short-term impact of 3 smoked cannabis preparations versus placebo on PTSD symptoms: a randomized cross-over clinical trial.","volume":"16","author":"Bonn-Miller","year":"2021","journal-title":"PLoS One"},{"key":"irv250005r42","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.psyneuen.2014.11.002","article-title":"The efficacy of nabilone, a synthetic cannabinoid, in the treatment of PTSD-associated nightmares: a preliminary randomized, double-blind, placebo-controlled cross-over design study.","volume":"51","author":"Jetly","year":"2015","journal-title":"Psychoneuroendocrinology"},{"issue":"2","key":"irv250005r43","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1089\/can.2020.0056","article-title":"The long-term, prospective, therapeutic impact of cannabis on post-traumatic stress disorder.","volume":"7","author":"Bonn-Miller","year":"2022","journal-title":"Cannabis Cannabinoid Res"},{"issue":"9","key":"irv250005r44","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.4088\/JCP.14m09475","article-title":"Marijuana use is associated with worse outcomes in symptom severity and violent behavior in patients with posttraumatic stress disorder.","volume":"76","author":"Wilkinson","year":"2015","journal-title":"J Clin Psychiatry"},{"key":"irv250005r45","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.socscimed.2019.06.005","article-title":"Patient-reported use of medical cannabis for pain, anxiety, and depression symptoms: systematic review and meta-analysis.","volume":"233","author":"Kosiba","year":"2019","journal-title":"Soc Sci Med"},{"issue":"1","key":"irv250005r46","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1159\/000534855","article-title":"Cannabis and anxiety: a critical review.","volume":"7","author":"Beletsky","year":"2024","journal-title":"Med Cannabis Cannabinoids"},{"key":"irv250005r47","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.drugalcdep.2017.03.030","article-title":"Dose-related effects of delta-9-THC on emotional responses to acute psychosocial stress.","volume":"177","author":"Childs","year":"2017","journal-title":"Drug Alcohol Depend"},{"issue":"6","key":"irv250005r48","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1038\/npp.2011.6","article-title":"Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-na\u00efve social phobia patients.","volume":"36","author":"Bergamaschi","year":"2011","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"irv250005r49","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1590\/1516-4446-2017-0015","article-title":"Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test.","volume":"41","author":"Linares","year":"2019","journal-title":"Braz J Psychiatry"},{"issue":"1","key":"irv250005r50","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1177\/026988119300700112","article-title":"Effects of ipsapirone and cannabidiol on human experimental anxiety.","volume":"7","author":"Zuardi","year":"1993","journal-title":"J Psychopharmacol"},{"issue":"1","key":"irv250005r51","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/0014-2999(74)90129-0","article-title":"Cannabidiol interferes with the effects of delta 9 - tetrahydrocannabinol in man.","volume":"28","author":"Karniol","year":"1974","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"irv250005r52","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/BF00432554","article-title":"Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects.","volume":"76","author":"Zuardi","year":"1982","journal-title":"Psychopharmacology (Berl)"},{"issue":"1","key":"irv250005r53","doi-asserted-by":"publisher","first-page":"16163","DOI":"10.1038\/s41598-024-66879-0","article-title":"Acute effects of cannabigerol on anxiety, stress, and mood: a double-blind, placebo-controlled, crossover, field trial.","volume":"14","author":"Cuttler","year":"2024","journal-title":"Sci Rep"},{"key":"irv250005r54","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2024.116049","article-title":"Therapeutic potential of cannabidiol (CBD) in anxiety disorders: a systematic review and meta-analysis.","volume":"339","author":"Han","year":"2024","journal-title":"Psychiatry Res"},{"issue":"12","key":"irv250005r55","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/S2215-0366(19)30401-8","article-title":"Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis.","volume":"6","author":"Black","year":"2019","journal-title":"Lancet Psychiatry"},{"key":"irv250005r56","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.psychres.2017.02.027","article-title":"Cannabis use and the course and outcome of major depressive disorder: a population based longitudinal study.","volume":"251","author":"Feingold","year":"2017","journal-title":"Psychiatry Res"},{"issue":"6","key":"irv250005r57","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.13025","article-title":"Associations of suicidality trends with cannabis use as a function of sex and depression status.","volume":"4","author":"Han","year":"2021","journal-title":"JAMA Netw Open"},{"key":"irv250005r58","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.jad.2016.02.007","article-title":"A literature review and meta-analyses of cannabis use and suicidality.","volume":"195","author":"Borges","year":"2016","journal-title":"J Affect Disord"},{"issue":"4","key":"irv250005r59","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1001\/jamapediatrics.2020.5494","article-title":"Association of cannabis use with self-harm and mortality risk among youths with mood disorders.","volume":"175","author":"Fontanella","year":"2021","journal-title":"JAMA Pediatr"},{"issue":"2","key":"irv250005r60","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1111\/sltb.12345","article-title":"The impact of cannabis use disorder on suicidal and nonsuicidal self-injury in Iraq\/Afghanistan-era veterans with and without mental health disorders.","volume":"48","author":"Kimbrel","year":"2018","journal-title":"Suicide Life Threat Behav"},{"issue":"2","key":"irv250005r61","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1111\/acps.12366","article-title":"Cannabis and bipolar disorder: does quitting cannabis use during manic\/mixed episode improve clinical\/functional outcomes?","volume":"131","author":"Zorrilla","year":"2015","journal-title":"Acta Psychiatr Scand"},{"issue":"1-3","key":"irv250005r62","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.jad.2009.02.007","article-title":"Predictors of switching from mania to depression in a large observational study across Europe (EMBLEM).","volume":"118","author":"Vieta","year":"2009","journal-title":"J Affect Disord"},{"issue":"1","key":"irv250005r63","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1097\/NMD.0b013e31819292a6","article-title":"Does cannabis use affect treatment outcome in bipolar disorder? a longitudinal analysis.","volume":"197","author":"van Rossum","year":"2009","journal-title":"J Nerv Ment Dis"},{"issue":"2","key":"irv250005r64","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1111\/j.1600-0447.2005.00692.x","article-title":"Evidence for three distinct classes of \u2018typical\u2019, \u2018psychotic\u2019 and \u2018dual\u2019 mania: results from the EMBLEM study.","volume":"113","author":"Haro","year":"2006","journal-title":"Acta Psychiatr Scand"},{"issue":"4","key":"irv250005r65","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1177\/07067437231209650","article-title":"Cannabidiol as an adjunctive treatment for acute bipolar depression: a pilot study: le cannabidiol comme traitement d\u2019appoint de la d\u00e9pression bipolaire aigu\u00eb: une \u00e9tude pilote.","volume":"69","author":"Pinto","year":"2024","journal-title":"Can J Psychiatry"},{"issue":"1","key":"irv250005r67","doi-asserted-by":"publisher","DOI":"10.1136\/bmjment-2023-300700","article-title":"Cause-specific excess mortality after first diagnosis of bipolar disorder: population-based cohort study.","volume":"26","author":"Palj\u00e4rvi","year":"2023","journal-title":"BMJ Ment Health"},{"issue":"4","key":"irv250005r68","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/S2215-0366(20)30074-2","article-title":"Psychiatric symptoms caused by cannabis constituents: a systematic review and meta-analysis.","volume":"7","author":"Hindley","year":"2020","journal-title":"Lancet Psychiatry"},{"issue":"10","key":"irv250005r69","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1080\/15622975.2022.2038797","article-title":"Consensus paper of the WFSBP task force on cannabis, cannabinoids and psychosis.","volume":"23","author":"D\u2019Souza","year":"2022","journal-title":"World J Biol Psychiatry"},{"issue":"4","key":"irv250005r70","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1176\/appi.ajp.2017.17020223","article-title":"Rates and predictors of conversion to schizophrenia or bipolar disorder following substance-induced psychosis.","volume":"175","author":"Starzer","year":"2018","journal-title":"Am J Psychiatry"},{"key":"irv250005r71","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1192\/bjp.187.6.510","article-title":"Cannabis-induced psychosis and subsequent schizophrenia-spectrum disorders: follow-up study of 535 incident cases.","volume":"187","author":"Arendt","year":"2005","journal-title":"Br J Psychiatry"},{"issue":"4","key":"irv250005r72","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1017\/S0033291719003532","article-title":"Annual incidence of cannabis-induced psychosis, other substance-induced psychoses and dually diagnosed schizophrenia and cannabis use disorder in Denmark from 1994 to 2016.","volume":"51","author":"Hjorth\u00f8j","year":"2021","journal-title":"Psychol Med"},{"issue":"2","key":"irv250005r73","doi-asserted-by":"publisher","first-page":"97","DOI":"10.3390\/brainsci10020097","article-title":"Factors moderating the association between cannabis use and psychosis risk: a systematic review.","volume":"10","author":"van der Steur","year":"2020","journal-title":"Brain Sci"},{"issue":"2","key":"irv250005r74","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.57868","article-title":"Changes in incident schizophrenia diagnoses associated with cannabis use disorder after cannabis legalization.","volume":"8","author":"Myran","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"3","key":"irv250005r75","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/S2215-0366(14)00117-5","article-title":"Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a case-control study.","volume":"2","author":"Di Forti","year":"2015","journal-title":"Lancet Psychiatry"},{"issue":"5","key":"irv250005r76","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/S2215-0366(19)30048-3","article-title":"The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study.","volume":"6","author":"Di Forti","year":"2019","journal-title":"Lancet Psychiatry"},{"issue":"11","key":"irv250005r77","doi-asserted-by":"publisher","first-page":"2926","DOI":"10.1017\/S0033291724000990","article-title":"Age-dependent association of cannabis use with risk of psychotic disorder.","volume":"54","author":"McDonald","year":"2024","journal-title":"Psychol Med"},{"key":"irv250005r78","doi-asserted-by":"publisher","first-page":"d738","DOI":"10.1136\/bmj.d738","article-title":"Continued cannabis use and risk of incidence and persistence of psychotic symptoms: 10 year follow-up cohort study.","volume":"342","author":"Kuepper","year":"2011","journal-title":"BMJ"},{"issue":"9","key":"irv250005r79","doi-asserted-by":"publisher","first-page":"3858","DOI":"10.1017\/S0033291722000502","article-title":"Risk-thresholds for the association between frequency of cannabis use and the development of psychosis: a systematic review and meta-analysis.","volume":"53","author":"Robinson","year":"2023","journal-title":"Psychol Med"},{"issue":"1","key":"irv250005r80","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/s41398-021-01330-w","article-title":"Cannabis, schizophrenia genetic risk, and psychotic experiences: a cross-sectional study of 109,308 participants from the UK Biobank.","volume":"11","author":"Wainberg","year":"2021","journal-title":"Transl Psychiatry"},{"issue":"3","key":"irv250005r81","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1093\/schbul\/sbac196","article-title":"Associations between cannabis use, polygenic liability for schizophrenia, and cannabis-related experiences in a sample of cannabis users.","volume":"49","author":"Johnson","year":"2023","journal-title":"Schizophr Bull"},{"issue":"11","key":"irv250005r82","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1001\/jamapsychiatry.2018.2309","article-title":"Effect of cannabidiol on medial temporal, midbrain, and striatal dysfunction in people at clinical high risk of psychosis: a randomized clinical trial.","volume":"75","author":"Bhattacharyya","year":"2018","journal-title":"JAMA Psychiatry"},{"issue":"3","key":"irv250005r83","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1038\/npp.2009.184","article-title":"Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology.","volume":"35","author":"Bhattacharyya","year":"2010","journal-title":"Neuropsychopharmacology"},{"issue":"1-3","key":"irv250005r84","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.schres.2011.04.017","article-title":"Cannabis with high cannabidiol content is associated with fewer psychotic experiences.","volume":"130","author":"Schubart","year":"2011","journal-title":"Schizophr Res"},{"issue":"6","key":"irv250005r85","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1038\/s41386-022-01478-z","article-title":"Does cannabidiol make cannabis safer? a randomised, double-blind, cross-over trial of cannabis with four different CBD:THC ratios.","volume":"48","author":"Englund","year":"2023","journal-title":"Neuropsychopharmacology"},{"issue":"12","key":"irv250005r86","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1038\/s41386-025-02175-3","article-title":"Does cannabidiol reduce the adverse effects of cannabis in schizophrenia? a randomised, double-blind, cross-over trial.","volume":"50","author":"Chesney","year":"2025","journal-title":"Neuropsychopharmacology"},{"key":"irv250005r87","doi-asserted-by":"publisher","DOI":"10.1177\/10870547251364575","article-title":"Cannabis use in a community-based sample of adults diagnosed with ADHD: prevalence, impact on symptoms, and stimulant side effects.","author":"Ryan","journal-title":"J Atten Disord"},{"issue":"11","key":"irv250005r88","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1177\/1087054716640109","article-title":"ADHD is highly prevalent in patients seeking treatment for cannabis use disorders.","volume":"24","author":"Notzon","year":"2020","journal-title":"J Atten Disord"},{"issue":"4","key":"irv250005r89","doi-asserted-by":"publisher","first-page":"427","DOI":"10.3109\/10826084.2013.841251","article-title":"Subtypes of attention deficit-hyperactivity disorder (ADHD) and cannabis use.","volume":"49","author":"Loflin","year":"2014","journal-title":"Subst Use Misuse"},{"issue":"5","key":"irv250005r90","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0156614","article-title":"\u201cI use weed for my ADHD\u201d: a qualitative analysis of online forum discussions on cannabis use and ADHD.","volume":"11","author":"Mitchell","year":"2016","journal-title":"PLoS One"},{"key":"irv250005r91","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.596601","article-title":"Cannabis and cognitive functioning: from acute to residual effects, from randomized controlled trials to prospective designs.","volume":"12","author":"Bourque","year":"2021","journal-title":"Front Psychiatry"},{"issue":"8","key":"irv250005r92","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.euroneuro.2017.05.005","article-title":"Cannabinoids in attention-deficit\/hyperactivity disorder: a randomised-controlled trial.","volume":"27","author":"Cooper","year":"2017","journal-title":"Eur Neuropsychopharmacol"},{"issue":"6","key":"irv250005r93","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1176\/appi.ajp.2015.15070907","article-title":"Prevalence and correlates of DSM-5 cannabis use disorder, 2012-2013: findings from the National Epidemiologic Survey on Alcohol and Related Conditions-III.","volume":"173","author":"Hasin","year":"2016","journal-title":"Am J Psychiatry"},{"issue":"7","key":"irv250005r95","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1111\/add.15770","article-title":"The effects of cannabis and alcohol on driving performance and driver behaviour: a systematic review and meta-analysis.","volume":"117","author":"Simmons","year":"2022","journal-title":"Addiction"},{"key":"irv250005r96","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e536","article-title":"Acute cannabis consumption and motor vehicle collision risk: systematic review of observational studies and meta-analysis.","volume":"344","author":"Asbridge","year":"2012","journal-title":"BMJ"},{"issue":"1","key":"irv250005r97","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1097\/CXA.0000000000000046","article-title":"Impact of cannabis use on road traffic collisions and safety at work: systematic review and meta-analysis.","volume":"10","author":"Els","year":"2019","journal-title":"Can J Addict"},{"issue":"1","key":"irv250005r98","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13643-022-02073-5","article-title":"The effect of medical cannabis on cognitive functions: a systematic review.","volume":"11","author":"Wieghorst","year":"2022","journal-title":"Syst Rev"},{"issue":"2","key":"irv250005r99","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1080\/03602532.2024.2346767","article-title":"Effects of cannabidiol and ?9-tetrahydrocannabinol on cytochrome P450 enzymes: a systematic review.","volume":"56","author":"Smith","year":"2024","journal-title":"Drug Metab Rev"},{"issue":"11","key":"irv250005r101","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1111\/epi.16355","article-title":"Coadministered cannabidiol and clobazam: preclinical evidence for both pharmacodynamic and pharmacokinetic interactions.","volume":"60","author":"Anderson","year":"2019","journal-title":"Epilepsia"},{"issue":"7","key":"irv250005r102","doi-asserted-by":"publisher","first-page":"615","DOI":"10.3390\/jpm11070615","article-title":"The impact of marijuana on antidepressant treatment in adolescents: clinical and pharmacologic considerations.","volume":"11","author":"Vaughn","year":"2021","journal-title":"J Pers Med"},{"issue":"1","key":"irv250005r103","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1097\/00004583-199701000-00016","article-title":"Case study: adverse effects of smoking marijuana while receiving tricyclic antidepressants.","volume":"36","author":"Wilens","year":"1997","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"5","key":"irv250005r104","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1007\/s00406-019-01091-0","article-title":"Buprenorphine-cannabis interaction in patients undergoing opioid maintenance therapy.","volume":"271","author":"Vierke","year":"2021","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"issue":"3","key":"irv250005r105","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.20cr13777","article-title":"A change in blood carbamazepine levels associated with cannabis use: implications for clinical practice.","volume":"82","author":"Ridout","year":"2021","journal-title":"J Clin Psychiatry"},{"issue":"9","key":"irv250005r106","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1001\/jamainternmed.2025.2366","article-title":"Cannabidiol and liver enzyme level elevations in healthy adults: a randomized clinical trial.","volume":"185","author":"Florian","year":"2025","journal-title":"JAMA Intern Med"},{"key":"irv250005r107","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1282831","article-title":"Systematic review of drug-drug interactions of delta-9-tetrahydrocannabinol, cannabidiol, and Cannabis.","volume":"15","author":"Nachnani","year":"2024","journal-title":"Front Pharmacol"},{"issue":"9","key":"irv250005r109","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.24511","article-title":"Analysis of state cannabis laws and dispensary staff recommendations to adults purchasing medical cannabis.","volume":"4","author":"Merlin","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"1","key":"irv250005r110","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s42238-021-00073-1","article-title":"Consensus recommendations on dosing and administration of medical cannabis to treat chronic pain: results of a modified Delphi process.","volume":"3","author":"Bhaskar","year":"2021","journal-title":"J Cannabis Res"},{"issue":"5","key":"irv250005r111","doi-asserted-by":"publisher","first-page":"714","DOI":"10.7326\/ANNALS-24-03319","article-title":"Cannabis or cannabinoids for the management of chronic noncancer pain: best practice advice from the American College of Physicians.","volume":"178","author":"Kansagara","year":"2025","journal-title":"Ann Intern Med"},{"issue":"2040","key":"irv250005r112","doi-asserted-by":"publisher","first-page":"n2040","DOI":"10.1136\/bmj.n2040","article-title":"Medical cannabis or cannabinoids for chronic pain: a clinical practice guideline.","volume":"374","author":"Busse","year":"2021","journal-title":"BMJ"},{"key":"irv250005r113","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2021.103381","article-title":"Lower-Risk Cannabis Use Guidelines (LRCUG) for reducing health harms from non-medical cannabis use: a comprehensive evidence and recommendations update.","volume":"99","author":"Fischer","year":"2022","journal-title":"Int J Drug Policy"},{"issue":"22","key":"irv250005r114","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1001\/jama.2020.8020","article-title":"Screening for unhealthy drug use: US Preventive Services Task Force Recommendation Statement.","volume":"323","author":"Krist","year":"2020","journal-title":"JAMA"},{"issue":"11","key":"irv250005r115","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.39772","article-title":"Validity of the Single-Item Screen-Cannabis (SIS-C) for cannabis use disorder screening in routine care.","volume":"5","author":"Matson","year":"2022","journal-title":"JAMA Netw Open"},{"key":"irv250005r116","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2023.109876","article-title":"Assessing the diagnostic utility of the Cannabis Use Disorder Identification Test - Revised (CUDIT-R) among veterans with medical and non-medical cannabis use.","volume":"247","author":"Myers","year":"2023","journal-title":"Drug Alcohol Depend"},{"issue":"2","key":"irv250005r117","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1089\/can.2022.0238","article-title":"Estimating THC consumption from smoked and vaped cannabis products in an online survey of adults who use cannabis.","volume":"9","author":"Budney","year":"2024","journal-title":"Cannabis Cannabinoid Res"},{"issue":"8","key":"irv250005r118","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.7326\/M21-4520","article-title":"Cannabis-based products for chronic pain: a systematic review.","volume":"175","author":"McDonagh","year":"2022","journal-title":"Ann Intern Med"},{"issue":"7","key":"irv250005r119","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1001\/jamapediatrics.2025.0689","article-title":"Prenatal cannabis use and neonatal outcomes: a systematic review and meta-analysis.","volume":"179","author":"Lo","year":"2025","journal-title":"JAMA Pediatr"},{"issue":"4","key":"irv250005r120","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1097\/AOG.0000000000006053","article-title":"ACOG Clinical Consensus No. 10: Cannabis Use During Pregnancy and Lactation.","volume":"146","year":"2025","journal-title":"Obstet Gynecol"},{"issue":"7","key":"irv250005r121","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1111\/add.15743","article-title":"Clinical management of cannabis withdrawal.","volume":"117","author":"Connor","year":"2022","journal-title":"Addiction"},{"key":"irv250005r122","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.drugalcdep.2018.09.029","article-title":"Mental health functioning and severity of cannabis withdrawal among medical cannabis users with chronic pain.","volume":"194","author":"Perron","year":"2019","journal-title":"Drug Alcohol Depend"},{"issue":"8","key":"irv250005r123","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1111\/add.15370","article-title":"Progression of cannabis withdrawal symptoms in people using medical cannabis for chronic pain.","volume":"116","author":"Coughlin","year":"2021","journal-title":"Addiction"},{"issue":"2","key":"irv250005r124","doi-asserted-by":"publisher","first-page":"106","DOI":"10.7326\/M18-0522","article-title":"Marijuana use, respiratory symptoms, and pulmonary function: a systematic review and meta-analysis.","volume":"169","author":"Ghasemiesfe","year":"2018","journal-title":"Ann Intern Med"},{"issue":"6","key":"irv250005r125","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1080\/00952990.2019.1627366","article-title":"Pulmonary effects of inhaled cannabis smoke.","volume":"45","author":"Tashkin","year":"2019","journal-title":"Am J Drug Alcohol Abuse"},{"issue":"12","key":"irv250005r126","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1001\/jamaoto.2024.2419","article-title":"Cannabis use and head and neck cancer.","volume":"150","author":"Gallagher","year":"2024","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"irv250005r4","volume-title":"Cannabis Policy Impacts Public Health and Health Equity","author":"National Academies of Sciences, Engineering, and Medicine","year":"2024"},{"key":"irv250005r16","unstructured":"Ayers? C, Harrod? C, Durbin? S, . Cannabis for the management of symptoms of PTSD: a living systematic review. Accessed August 11, 2025. https:\/\/www.cannabisevidence.org\/evidence-syntheses\/ptsd\/"},{"key":"irv250005r17","unstructured":"Ayers? C, Shaw? B, Robalino? R, . Cannabis for anxiety and mood disorders. Accessed August 11, 2025. https:\/\/www.cannabisevidence.org\/evidence-syntheses\/anxiety_and_mood_disorders\/"},{"key":"irv250005r23","unstructured":"Ayers? C, Robalino? S, Shaw? B, Ward? R, Kansagara? D. Prevalence and risk of developing cannabis use disorder in adults who use cannabis. Accessed May 14, 2025. https:\/\/www.cannabisevidence.org\/evidence-syntheses\/adult-cannabis-use-disorder\/"},{"key":"irv250005r24","unstructured":"Department of Veterans Affairs, Department of Defense. VA\/DoD clinical practice guideline for the management of substance use disorders. Accessed July 10, 2025. https:\/\/www.healthquality.va.gov\/guidelines\/MH\/sud\/VA-DoD-SUD-CPG_Final_for-508_v3.pdf"},{"key":"irv250005r25","unstructured":"Durbin? S, Ayers? C, Yeddala? S, Shaw? B, Robalino? R, Kansagara? D. Pharmacotherapy for the treatment of cannabis use disorder. Accessed July 10, 2025. https:\/\/www.cannabisevidence.org\/evidence-syntheses\/pharmaceuticals-for-cannabis-use-disorder\/"},{"key":"irv250005r29","unstructured":"Systematically Testing the Evidence on Marijuana. About. Accessed August 8, 2025. https:\/\/www.cannabisevidence.org\/about\/"},{"key":"irv250005r30","unstructured":"Systematically Testing the Evidence on Marijuana. Living systematic review methods. Accessed October 9, 2025. https:\/\/www.cannabisevidence.org\/about\/living-systematic-review-methods\/"},{"key":"irv250005r66","unstructured":"Cannabidiol for Bipolar Depression (CBD-BD) (CBD-BD). ClinicalTrials.gov identifier: NCT05867849. Updated April 23, 2025. Accessed June 6, 2023. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05867849"},{"key":"irv250005r94","unstructured":"Meyer? C, Callahan? M, Grant? I. Cannabis and cognition. Accessed October 15, 2025. https:\/\/www.cannabisevidence.org\/clinician-resources\/clinician-briefs\/cannabis-and-cognition\/"},{"key":"irv250005r100","unstructured":"Penn State College of Medicine. CANN-DIR: CANNabinoid Drug Interaction Review. Accessed December 2, 2025. https:\/\/cann-dir.psu.edu\/"},{"key":"irv250005r108","unstructured":"Systematically Testing the Evidence on Marijuana. Policy map. Accessed October 27, 2025. https:\/\/www.cannabisevidence.org\/policy\/"}],"container-title":["JAMA Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/articlepdf\/2846007\/jamainternal_kansagara_2026_rv_250005_1777045071.4851.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T15:01:19Z","timestamp":1777906879000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/fullarticle\/2846007"}},"subtitle":["A Review"],"short-title":[],"issued":{"date-parts":[[2026,5,1]]},"references-count":126,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamainternmed.2025.8215","relation":{},"ISSN":["2168-6106"],"issn-type":[{"value":"2168-6106","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,1]]}}}